These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 31305186

  • 21. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials.
    Puig L, Tsai TF, Bhutani T, Uy J, Ramachandran P, Song M, You Y, Gooderham M, Lebwohl M.
    J Eur Acad Dermatol Venereol; 2020 Aug; 34(8):1744-1749. PubMed ID: 32289190
    [Abstract] [Full Text] [Related]

  • 22. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2.
    Reich K, Song M, Li S, Jiang J, Youn SW, Tsai TF, Choe YB, Huang YH, Gordon KB.
    J Dermatol; 2019 Dec; 46(12):1141-1152. PubMed ID: 31631377
    [Abstract] [Full Text] [Related]

  • 23. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations.
    Jo SJ, Huang YH, Tsai TF, Kim BS, Reich K, Saadoun C, Chang CL, Yang YW, Youn SW.
    J Dermatol; 2023 Sep; 50(9):1180-1189. PubMed ID: 37341137
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies.
    Gordon KB, Blauvelt A, Foley P, Song M, Wasfi Y, Randazzo B, Shen YK, You Y, Griffiths CEM.
    Br J Dermatol; 2018 Jan; 178(1):132-139. PubMed ID: 28940259
    [Abstract] [Full Text] [Related]

  • 26. Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.
    Puig L.
    Expert Rev Clin Immunol; 2019 Jun; 15(6):589-597. PubMed ID: 30920855
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.
    Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.
    J Am Acad Dermatol; 2012 Feb; 66(2):e67-76. PubMed ID: 21616560
    [Abstract] [Full Text] [Related]

  • 29. Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years.
    Griffiths CEM, Papp KA, Kimball AB, Randazzo B, Song M, Li S, Shen YK, Blauvelt A.
    J Drugs Dermatol; 2018 Aug 01; 17(8):826-832. PubMed ID: 30124721
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.
    Ferris LK, Ott E, Jiang J, Hong HC, Li S, Han C, Baran W.
    J Dermatolog Treat; 2020 Mar 01; 31(2):152-159. PubMed ID: 30887876
    [Abstract] [Full Text] [Related]

  • 31. Efficacy of Guselkumab in Treating Nails, Scalp, Hands, and Feet in Patients with Psoriasis and Self-reported Psoriatic Arthritis.
    Orbai AM, Chakravarty SD, You Y, Shawi M, Yang YW, Merola JF.
    Dermatol Ther (Heidelb); 2023 Nov 01; 13(11):2859-2868. PubMed ID: 37713133
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACH.
    Poulin Y, Crowley JJ, Langley RG, Unnebrink K, Goldblum OM, Valdecantos WC.
    J Eur Acad Dermatol Venereol; 2014 Jul 01; 28(7):882-90. PubMed ID: 23790018
    [Abstract] [Full Text] [Related]

  • 33. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial.
    Shikiar R, Heffernan M, Langley RG, Willian MK, Okun MM, Revicki DA.
    J Dermatolog Treat; 2007 Jul 01; 18(1):25-31. PubMed ID: 17365264
    [Abstract] [Full Text] [Related]

  • 34. Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
    Lebwohl MG, Merola JF, Rowland K, Miller M, Yang YW, Yu J, You Y, Chan D, Thaçi D, Langley RG.
    Br J Dermatol; 2023 Jul 07; 189(1):42-52. PubMed ID: 37022762
    [Abstract] [Full Text] [Related]

  • 35. Nail psoriasis dynamics during biologic treatment and withdrawal in patients with psoriasis who may be at high risk of developing psoriatic arthritis: a post hoc analysis of the VOYAGE 2 randomized trial.
    Tillett W, Egeberg A, Sonkoly E, Gorecki P, Tjärnlund A, Buyze J, Wegner S, McGonagle D.
    Arthritis Res Ther; 2023 Sep 15; 25(1):169. PubMed ID: 37715294
    [Abstract] [Full Text] [Related]

  • 36. The Effect of Guselkumab on Work Productivity in Biologic-Naïve Patients with Active Psoriatic Arthritis Through Week 52 of the Phase 3, Randomized, Placebo-Controlled DISCOVER-2 Trial.
    Curtis JR, McInnes IB, Rahman P, Gladman DD, Peterson S, Agarwal P, Yang F, Kollmeier AP, Hsia EC, Shiff NJ, Zhou B, Han C, Shawi M, Tillett W, Mease PJ.
    Adv Ther; 2022 Oct 15; 39(10):4613-4631. PubMed ID: 35947349
    [Abstract] [Full Text] [Related]

  • 37. The real world impact of adalimumab on quality of life and the physical and psychological effects of moderate-to-severe psoriasis: a UK prospective, multicenter, observational study.
    Leman J, Walton S, Layton AM, Ward KA, McBride S, Cliff S, Downs A, Landeira M, Bewley A.
    J Dermatolog Treat; 2020 May 15; 31(3):213-221. PubMed ID: 30897016
    [Abstract] [Full Text] [Related]

  • 38. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
    Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.
    Value Health; 2018 Jan 15; 21(1):1-8. PubMed ID: 29304933
    [Abstract] [Full Text] [Related]

  • 39. Ustekinumab decreases work limitations, improves work productivity, and reduces work days missed in patients with moderate-to-severe psoriasis: results from PHOENIX 2.
    Reich K, Schenkel B, Zhao N, Szapary P, Augustin M, Bourcier M, Guenther L, Langley RG.
    J Dermatolog Treat; 2011 Dec 15; 22(6):337-47. PubMed ID: 21034290
    [Abstract] [Full Text] [Related]

  • 40. Guselkumab: A Review in Moderate to Severe Plaque Psoriasis.
    Al-Salama ZT, Scott LJ.
    Am J Clin Dermatol; 2018 Dec 15; 19(6):907-918. PubMed ID: 30467781
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.